×
For best experience we recommend to activate Javascript in your browser.
Recombinant MUC16 (Oregovomab Biosimilar) antibody
The Human Monoclonal anti-MUC16 (Oregovomab Biosimilar) antibody (ABIN7675797) specifically detects MUC16 (Oregovomab Biosimilar) in BLI, ELISA, FACS, Func and SPR.
The antibody is reactive with Human samples.
Catalog No. ABIN7675797
$346.15
Plus shipping costs $50.00
1 mg ABIN7581578
100 μg ABIN7675797
1 mg ABIN7581578
100 μg ABIN7675797
Delivery in 10 to 12 Business Days
Quick Overview for Recombinant MUC16 (Oregovomab Biosimilar) antibody (ABIN7675797)
Target
MUC16 (Oregovomab Biosimilar)
Antibody Type
Recombinant Antibody
Reactivity
Human
Host
All hosts for MUC16 (Oregovomab Biosimilar) antibodies
Human
Clonality
All clonalities for MUC16 (Oregovomab Biosimilar) antibodies
Monoclonal
Conjugate
All conjugates for MUC16 (Oregovomab Biosimilar) antibodies
This MUC16 (Oregovomab Biosimilar) antibody is un-conjugated
Application
Bio-Layer Interferometry (BLI), ELISA, Flow Cytometry (FACS), Functional Studies (Func), Surface Plasmon Resonance (SPR)
Product Details anti-MUC16 (Oregovomab Biosimilar) Antibody
(hide)
Expression System
CHO Cells
Purpose
Anti-MUC16 Reference Antibody (oregovomab)
Characteristics
Anti-MUC16 Reference Antibody (oregovomab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
Purity
>95 %
Isotype
IgG1
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Lyophilized
Concentration
1 mg/mL
Buffer
25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
Storage
4 °C,-80 °C
Storage Comment
+4°C,-80°C
Target Details for MUC16 (Oregovomab Biosimilar)
(hide)
Target
MUC16 (Oregovomab Biosimilar)
Target Type
Biosimilar
Molecular Weight
145.5 kDa
UniProt
Q8WXI7
Recently viewed
(hide)
You are here:
Homepage
Recombinant anti-MUC16 (Oregovomab Biosimilar) antibody (ABIN7675797)
Chat with us , powered by LiveChat